Navigation Links
Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
Date:5/26/2011

nvolve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these for
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
2. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. Biovista Announces a Drug Repositioning Collaboration With Pfizer
5. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
6. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
7. Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView
8. Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone)
9. Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
10. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
11. Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... , , , , , , ... , University Hospital and Medical School of the Dutch-speaking Brussels Free , ... , , , , , ... , Preimplantation diagnosis (PGD) is a very ...
... gradient , , , , , , , ... and Research, University , of Malaya, Kuala Lumpur, Malaysia , , , , ... , , ... , , ...
... , Ravindran Thayran , Institute ... , , , , , ... RT-PCR by using Eppendorf's Mastercycler gradient , , ... often carried out at the Institute of Health and Community Medicine, Universiti , ...
Cached Biology Technology:The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 2The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 4The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 5Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 2Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 4Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 5Optimized Dengue RT-PCR 2Optimized Dengue RT-PCR 3
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
(Date:1/22/2015)... , Europe,s most ... Patent Office to present a video retrospective of the most exciting ... Christofer Toumazou and Sophie Wilson   ... the Award   Starting on 22 January 2015 on   ...
(Date:12/22/2014)... Conn. , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market, ... Apollo Robbins for the 2015 International CES debut ... Apollo Robbins will be at the NXT-ID booth January ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... not free of risk. Since 2005, the poison emergency ... have registered a total of 17 patients with health ... Mller and his coauthors describe the documented cases of ... International (Dtsch Arztebl Int 2009; 106(13): 218-22). ...
... eco-friendly residential house made of bamboo now stands in Changsha, ... Xiao, a professor at the USC Viterbi School of Engineering ... Bamboo, Timber and Composite Structures of the Hunan University, China ... kind in the world. It uses the GluBam ...
... for metastatic prostate cancer has shown considerable promise in early ... current drugs. , Of 30 men who received low ... trial designed to evaluate safety, 22 showed a sustained decline ... blood. Phase III clinical trials are planned to evaluate the ...
Cached Biology News:A full-sized California-style home made of bamboo 2New medications show promise in treating drug-resistant prostate cancer 2New medications show promise in treating drug-resistant prostate cancer 3New medications show promise in treating drug-resistant prostate cancer 4
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: